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Myogenesis is conducted by transcription factors including MyoD and myogenin. Myogenin is
known to be polyubiquitinated by SCF (Skp1/Cullin 1/F-box protein) followed by proteasomal degra-
dation, though the participating F-box protein is remaining unidentiﬁed. In this study, we found
that myogenin in differentiated myoblasts is destabilized by muscle atrophy-inducing dexametha-
sone and that MAFbx (muscle atrophy F-box protein) is increased in atrophying myotubes. MAFbx
overexpression resulted in MG132-sensitive reduction of myogenin. Myogenin had a MAFbx-recog-
nition motif and interacted with MAFbx. MAFbx activated polyubiquitination of myogenin. The
results of this study suggest that MAFbx functions as an F-box protein for ubiquitination of myog-
enin.
Structured summary:
MINT-7222713: Myogenin (uniprotkb:P12979) physically interacts (MI:0914) with MAFbx (uni-
protkb:Q9CPU7) by anti tag coimmunoprecipitation (MI:0007)
MINT-7222741: Myogenin (uniprotkb:P12979) physically interacts (MI:0914) with MAFbx (uni-
protkb:Q9CPU7) by anti bait coimmunoprecipitation (MI:0006)
MINT-7222726: Myogenin (uniprotkb:P12979) and MAFbx (uniprotkb:Q9CPU7) colocalize (MI:0403) by
ﬂuorescence microscopy (MI:0416)
MINT-7222760: Myogenin (uniprotkb:P12979) physically interacts (MI:0914) with Ubiquitin (uni-
protkb:P62991) by anti bait coimmunoprecipitation (MI:0006)
 2009 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction ligases, they contain a speciﬁc target-recognition subunit [4]. SCF isMuscle proteins are rapidly broken down in adaptation to vari-
ous physiological conditions and diseases [1,2]. This protein degra-
dation is driven by the ubiquitin proteasome system (UPS) [3]. In
this system, proteins subjected to degradation are covalently
linked to a ubiquitin (Ub) chain by a cascade involving Ub-activat-
ing E1 enzyme, Ub-conjugating E2 enzyme, and Ub ligase. Acti-
vated Ub is transferred to a target protein by Ub ligase and the
resultant polyubiquitinated proteins are degraded by proteasome.
Though E1 and E2 enzymes have no apparent target speciﬁcity, Ub
ligase selectively binds to a target protein. As for multi-subunit Ubon behalf of the Federation of Euro
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amura).one such multi-subunit Ub ligase, consisting of Skp1, cullin1 and F-
box protein. The F-box protein binds directly to the substrate [5].
MAFbx (muscle atrophy F-box protein)/Atrogin-1 was identiﬁed
as a muscle-speciﬁc F-box protein [6,7]. Gene expression of MAFbx
is elevated during muscle atrophy induced by dexamethasone
(Dex) and several stresses [6]. Tintignac et al. [8] found that MyoD
is degraded by MAFbx-containing SCF-mediated UPS. MyoD, which
functions in an early stage of myogenesis, is a member of the fam-
ily of muscle-speciﬁc bHLH (basic helix-loop-helix) transcription
factors [9–11]. An EGLQALLR motif in helix 2 of MyoD functions
as a MAFbx-recognizing motif, and LXXLL sequence (underlined)
has been designated as a core motif [8]. MAFbx contains multiple
protein-interacting motifs in addition to an F-box motif [7,8].
Myogenin, another member of the MyoD family, functions in the
middle stage of myogenesis [9]. Unlike MyoD, it has not been clar-
iﬁed whether myogenin level alters during muscle atrophy and
hypertrophy. Although we found that myogenin is degraded by
SCF [12], its F-box protein has not yet been identiﬁed. In this study,
we demonstrated that myogenin binds to MAFbx in cells and that
MAFbx participates in polyubquitination and degradation of
myogenin.pean Biochemical Societies.
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2.1. Cell culture, reagent treatment, and transfection
Mouse C2C12 myoblasts were cultured in DMEM-based growth
medium (GM) supplemented with 20% fetal calf serum. For myo-
genic differentiation, GM was exchanged with differentiation med-
ium (DM) consisting of DMEM and 2% horse serum [12]. Dex
(Sigma–Aldrich) and insulin-like growth factor-1 (IGF-1) (Sigma–
Aldrich) were added to the DM at 10 lM and 10 ng/ml, respec-
tively, and incubated for 24 h. Cos7 cells were cultured in DMEM
with 10% fetal calf serum. When required, MG132 (Biomol) was
added to media 4–6 h before cell harvest. Cells were transfected
with an indicated combination of expression plasmids (10 lg/
100 mm dish) using a LipofectAMINE and PLUS reagent
(Invitrogen).
2.2. DNAs and plasmids
To isolate mouse MAFbx cDNA, total RNA of differentiated and
Dex-treated C2C12 cells was extracted with an RNeasy RNA
extraction kit (Quiagen). RT-PCR was performed using an RNA
PCR kit (Takara). Mouse MAFbx cDNA was ampliﬁed by PCR using
50-CCATGCCGTTCCTTGGGCAG (forward) and 50-AAGTGTTGT
CGTGTGCTGGG (reverse) primers. The ampliﬁed MAFbx cDNA
was cloned in pGEM T-Easy vector (Promega) to construct pGEM-
MAFbx. For construction of HA-tagged (HA-MAFbx) and Flag-
tagged (FLAG-MAFbx) expression plasmids, an EcoRI fragment of
pGEM-MAFbx was inserted into HA and FLAG tag-carrying pcDNA
vectors (Invitrogen), respectively. A BamHI–XbaI fragment of
pGEM-MAFbx was inserted into pEGFP-N1 vector (Clontech) to
construct GFP-MAFbx that expresses GFP-fused MAFbx protein.
Other plasmids were described before [12,13].
2.3. RNA interference
Small interference RNA (siRNA) was prepared with a Silencer
siRNA Construction kit (Ambion). The sequences for targeting
mouse MAFbx was 50-AAGCGCTTCTTGGATGAGAAA [14]. An siRNA
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was in-
cluded in the kit. A set of 29-mer oligodeoxynucleotides for MAFbx
(sense: 50-AAGCGCTTCTTGGATGAGAAACCTGTCTC and antisense:
50-AATTTCTCATCCAAGAAGCGCCCTGTCTC) contains a correspond-
ing siRNA sequence and ﬂanking sequences complementary to     Dex     0 
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Fig. 1. Amounts of myogenin and MAFbx in reagent-treated differentiated cells. Gene ex
and immunoblotting, respectively. An asterisk in the middle part of panel B indicates athe T7 primer. Cells were transfected with 50 nM siRNA in mole-
cule molarity for each gene.
2.4. Immunoﬂuorescence staining
Cell ﬁxation with paraformaldehyde, permealization with Tri-
ton X-100 and interaction with a primary antibody were the same
as described before [12].
2.5. Preparation of cell extracts and immunoblotting
Cells were lysed with 1% Triton X-100-containing TNE buffer
(10 mM Tris–HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, and 10%
glycerol) [15] supplemented with protease inhibitor mixture (at ﬁ-
nal concentrations of 1 mM for benzamidine–HCl, 1 lg/ml for pep-
statin A, 0.5 mM for phenylmethylsulfonyl ﬂuoride, and 1 lg/ml
for leupeptin). The whole cell extracts were collected and protein
concentration was determined [16]. For immunoblotting, proteins
(5–30 lg) were separated by SDS–polyacrylamide gel electropho-
resis (PAGE). Procedures for immunoblotting were essentially the
same as described before [16].
2.6. Immunoprecipitation
Immunoprecipitation was performed as described before [12].
To detect ubiquitination of myogenin (Fig. 4), whole cell extracts
were prepared in RIPA buffer (TNE buffer containing 1% NP-40,
0.5% sodium deoxycholate, and 0.1% SDS) containing the protease
inhibitor mixture, 25 lM MG132, and 20 mM N-ethylmaleimide
and then incubated with protein G-Sepharose beads (GE Health-
care Bioscience) for 1 h. The supernatant fraction was incubated
with anti-myogenin antibody (Pharmingen) overnight. The materi-
als were incubated with protein G-Sepharose beads for 90 min fol-
lowed by washing with the same buffer used in cell lysis.
Immunocomplexes were eluted with SDS sample buffer by boiling
for 4 min. Proteins were detected by immunoblotting with a corre-
sponding antibody.
3. Results
3.1. Effects of Dex and IGF-1 on differentiated C2C12 cells
First, we investigated the expression of myogenin in myotube-
atrophying Dex-treated differentiated C2C12 cells. C2C12
myoblasts differentiated to myotubes in the DM, and someα−β actin
   3     6     12   24 (hr)
     2      3     4    5
α−myogenin
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pression (A) and proteins (B) of myogenin and MAFbx were determined by RT-PCR
MAFbx isoform. C2C12 cells were treated with Dex for 24 h.
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mentary Fig. S1). In this in vitro myogenesis, treatment of cells
with Dex resulted in impairment of the differentiated cells (Sup-
plementary Fig. S1), and apoptosis occurred when cells were ex-
posed to Dex for a longer time (data not shown). IGF-1, which
maintains muscles and induces muscle hypertrophy [17], showedMyoD 
myogenin 
HLH
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Fig. 2. Interaction of myogenin and MAFbx. (A) Schematic representation of structures of
domain (solid box) of MyoD and myogenin were aligned. MAFbx-recognizing motif w
enclosed with boxes. The core in the MAFbx-recognizing motif is shown as a thick bar. (
FLAG-myogenin- or HA-MAFbx-overexpressing cells were immunoprecipitated with ant
antibody (lanes 4–6). Lanes 1–3 represent results without immunoprecipitation. (C) Loc
with FLAG-myogenin- and GFP-MAFbx-expressing plasmids were incubated in GM for 2
and observed with a ﬂuorescent microscope. A merged image from GFP-MAFbx and m
shown.
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Fig. 3. Destabilization of myogenin by MAFbx. (A) FLAG-myogenin-expressing C2C12 c
were detected by immunoblotting. MG132 was also added (lanes 5 and 6). (B) Stabilizati
siRNA of MAFbx.a signiﬁcant over-growth effect (Supplementary Fig. S1G and H).
Next, we determined mRNA and protein of myogenin in Dex-trea-
ted differentiated cells. Dex treatment for 24 h reduced myogenin
protein to an almost undetectable level (Fig. 1B, lane 5), whereas
amounts of myogenin mRNA did not change (Fig. 1A). Myogenin
was thus demonstrated to be degraded in atrophying myotubes,GFP-MAFbx myogenin
merge DAPI
C
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ith seven amino acids of MyoD [8] and its corresponding region of myogenin are
B) Interaction between exogenous myogenin and MAFbx in C2C12 cells. Extracts of
i(a)-FLAG antibody, and MAFbx and myogenin were detected with a corresponding
alization of exogenously expressed myogenin and MAFbx. C2C12 cells transfected
4 h, treated with 10 lM MG132 for 2 h, immunostained with a-myogenin antibody,
yogenin panels and nucleus staining with DAPI (diamidino phenylindole) are also
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myogenin was increase by IGF-1, whereas its mRNA level did not
change (data not shown). We also found that MAFbx gene expres-
sion was remarkably stimulated and repressed by Dex and IGF-1,
respectively (data not shown). MAFbx protein increased in atro-
phying cells (Fig. 2B) as previously reported [7].
3.2. Interaction between myogenin and MAFbx
The above results imply a negative correlation between altera-
tions in myogenin and MAFbx. MyoD has been demonstrated to
bind to MAFbx via the EGLQALLR motif within helix 2 (Fig. 2A),
and a core region of EGLQALLR (LXXLL motif, underlined) is desig-
nated as a MAFbx-binding signature [8]. Since this signature motif
was detected in helix 2 of myogenin (Fig. 2A), we investigated the
interaction of MAFbx and myogenin in C2C12 cells by immunopre-
cipitation and immunoblotting in an overexpression condition. It
was found that MAFbx-including immunocomplexes contain
myogenin (Fig. 2B, lane 6). Furthermore, we examined the localiza-
tion of MAFbx in cells and found that exogenously expressed GFP-
MAFbx and FLAG-myogenin were co-localized (Fig. 2C). It was
clearly demonstrated that both MAFbx and myogenin were local-
ized in nuclei (Fig. 2C). GFP alone was distributed throughout a cell
and did not co-localized with myogenin (data not shown). The
ﬁndings thus suggested that MAFbx is physically associated with
myogenin in C2C12 cells.
3.3. MAFbx-dependent reduction of myogenin in differentiated cells
Myogenin in C2C12 cells was determined in an overexpression
condition. FLAG-myogenin was decreased when HA-MAFbx was
expressed (Fig. 3A, lanes 2 vs. 3 and 4). Furthermore, a high myog-
enin level was maintained when the proteasome inhibitor MG1321    2    3                 4     5     6                    
*
*
LC
HC
IB :α-HA
IB :α-FLAG
(kDa)
175
83
62
47
32.5
32.5
HA-Ub                
FLAG-myogenin  
FLAG-MAFbx     
      +
tupni IP: α ninegoym-
-
-
- --
-
+
--
-
---
+++
+
IB :α-FLAG
      (LE)
Fig. 4. Increase in polyubiquitinated myogenin in MAFbx-overexpressing cells. Cos7 ce
eight hours after transfection, cells were treated with 25 lM MG132 for 4 h, lysed, and
(lanes 1–3 and 7–10) and in immunoprecipitates (lanes 4–6 and 11–14) were detected
polyubiquitinated myogenin, non-speciﬁc band (asterisks), and immunoglobulin heavy
lanes 2 and 3 when the blot was exposed for longer time. Long exposure (LE) data of thwas added (Fig. 3A, lanes 5 and 6). We further applied MAFbx siR-
NA in this assay and found that MAFbx knockdown restored the le-
vel of myogenin (Fig. 3B). Taken together, the results suggested
that MAFbx destabilizes intracellular myogenin. Since myogenin
was considered to be ubiquitinated by MAFbx-containing SCF, we
investigated in vivo ubiquitination of exogenously expressed
myogenin. Cells overexpressing HA-Ub and FLAG-myogenin were
co-transfected with increased amounts of FLAG-MAFbx. HA signals
were clearly observed in high-molecular-weight regions of the gel
(Fig. 4, lanes 14 vs. 12), whereas these bands were not observed
when HA-Ub was omitted (lanes 4–6). These results suggest poly-
ubiquitination of myogenin.4. Discussion
Although MAFbx works as a target-recognizing component of
SCF in muscles [6,7], no protein has so far been reported as a target
of MAFbx except for MyoD [8]. Since MAFbx interacts with myog-
enin and enhances its ubiquitination (Figs. 2 and 4) and since
MAFbx stimulates MG132-sensitive myogenin degradation
(Fig. 3), it is thought that MAFbx is a myogenin-engaged F-box pro-
tein of SCF. Consistently, MAFbx gene expression was increased
and decreased when differentiated C2C12 cells were treated with
Dex (Fig. 1) and IGF-1 (data not shown), respectively. Myogenin
and MyoD are presumably degraded by a common mechanism.
We speculate that physiologically occurring Dex-induced muscle
atrophy is also involved in MAFbx-related degradation of myoge-
nin in addition to MyoD.
Since myogenin belongs to the MyoD family [9], we expected
myogenin to also be a target of MAFbx. However, Myf-5 does not
bind to MAFbx [8] even though it also belongs to the MyoD family.
EGLQALLR sequence has been identiﬁed as a MAFbx-recognition  7    8     9   10           11    12   13    14  
 Poly-Ub
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lls were transfected with the indicated combination of expression plasmids. Forty-
immunoprecipitated with a-myogenin antibody. Proteins in the whole cell extract
with a-HA (for Ub) and a-FLAG (for myogenin and MAFbx) antibodies. Positions of
chain (HC) & light chain (LC) are indicated. FLAG-myogenin signals can be seen in
e lower panel for lanes 1–3 were also shown.
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recognition motif is thought to be critical for MyoD to bind to
MAFbx. This core motif is also present in the MyoD-binding region
of MAFbx. Both myogenin (ERLQALLS) and Myf-5 (ESLQELLR) have
the consensus core motif in the hypothetical MAFbx-recognition
motif. However, alanine in the core motif of MyoD, which is also
conserved for myogenin, is exchanged with glutamic acid in Myf-
5 (Fig. 2A). Consequently, the entire sequence of the core motif
may be required for MAFbx binding. Alternatively, the second ami-
no acid in the recognition motif might participate in target recog-
nition. We found in data bases that the core motif of MyoD and
myogenin is conserved in mammals, whereas those in lower verte-
brates and invertebrates exhibit less conservation and no conser-
vation, respectively. On the other hand, those of Myf-5 and MRF4
are essentially not conserved. Therefore, MyoD family proteins
can be classiﬁed into two groups in a sense of protein degradation.
Nuclear localization of MAFbx (Fig. 2C) is consistent with the
fact that targets of MAFbx identiﬁed previously (i.e., MyoD) [8]
and in this study (i.e., myogenin) are both nucleus-localizing tran-
scription factors. MuRF1 (muscle RING-ﬁnger protein-1) is another
class of muscle-speciﬁc Ub ligase [6]. MuRF1 interacts with several
cytoplasmic enzymes and some of them are actually degraded by
MuRF1-mediated UPS [18]. Moreover, MuRF1 degrades many mus-
cle-related myoﬁbrillar proteins [19–21]. These lines of evidence
imply that MuRF1 functions mainly in the cytoplasm, and
MAFbx-containing SCF complex and MuRF1 might have a speciﬁc
role in degradation of muscle proteins.
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